| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 18 | 2024 | 656 | 1.980 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2023 | 661 | 0.820 |
Why?
|
| Herpesvirus 4, Human | 5 | 2023 | 119 | 0.750 |
Why?
|
| CpG Islands | 11 | 2024 | 158 | 0.740 |
Why?
|
| Cytosine | 5 | 2015 | 128 | 0.690 |
Why?
|
| Restriction Mapping | 2 | 2018 | 156 | 0.680 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2023 | 131 | 0.680 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 863 | 0.560 |
Why?
|
| Epigenesis, Genetic | 10 | 2023 | 502 | 0.560 |
Why?
|
| DNA-Binding Proteins | 8 | 2023 | 1240 | 0.560 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 478 | 0.550 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 3 | 2022 | 25 | 0.530 |
Why?
|
| Mixed Function Oxygenases | 5 | 2023 | 69 | 0.510 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2018 | 393 | 0.490 |
Why?
|
| Erythroid Cells | 1 | 2013 | 14 | 0.470 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 55 | 0.460 |
Why?
|
| Erythropoiesis | 1 | 2013 | 51 | 0.460 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 10 | 2023 | 55 | 0.450 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 153 | 0.430 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 336 | 0.430 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 566 | 0.410 |
Why?
|
| Leukemia | 4 | 2023 | 321 | 0.400 |
Why?
|
| Dioxygenases | 5 | 2021 | 75 | 0.390 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 970 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 1256 | 0.360 |
Why?
|
| Embryonic Stem Cells | 3 | 2019 | 80 | 0.350 |
Why?
|
| Virus Latency | 4 | 2023 | 33 | 0.310 |
Why?
|
| 5-Methylcytosine | 5 | 2015 | 113 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 267 | 0.290 |
Why?
|
| Genome, Viral | 3 | 2022 | 78 | 0.290 |
Why?
|
| Aging | 3 | 2023 | 712 | 0.280 |
Why?
|
| Chromatin | 4 | 2023 | 396 | 0.280 |
Why?
|
| CCCTC-Binding Factor | 3 | 2023 | 18 | 0.270 |
Why?
|
| Mutation | 7 | 2021 | 4097 | 0.270 |
Why?
|
| Neoplasm, Residual | 3 | 2005 | 176 | 0.270 |
Why?
|
| Cell Line, Tumor | 11 | 2021 | 2538 | 0.270 |
Why?
|
| Humans | 46 | 2024 | 88611 | 0.260 |
Why?
|
| RNA | 4 | 2024 | 575 | 0.250 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 659 | 0.230 |
Why?
|
| Transcription Factors | 6 | 2024 | 1647 | 0.230 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 92 | 0.220 |
Why?
|
| Animals | 18 | 2024 | 27233 | 0.220 |
Why?
|
| Mice | 12 | 2024 | 11710 | 0.220 |
Why?
|
| Drug Overdose | 1 | 2023 | 70 | 0.210 |
Why?
|
| Databases, Genetic | 1 | 2024 | 263 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 169 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 1184 | 0.210 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2023 | 103 | 0.210 |
Why?
|
| Paraganglioma | 1 | 2022 | 16 | 0.200 |
Why?
|
| Pheochromocytoma | 1 | 2022 | 50 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2023 | 169 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 358 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 59 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2022 | 82 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 74 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 109 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2406 | 0.190 |
Why?
|
| Adenoma | 1 | 2023 | 243 | 0.190 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 179 | 0.180 |
Why?
|
| Carcinogenesis | 2 | 2023 | 207 | 0.180 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 269 | 0.180 |
Why?
|
| Transcriptome | 2 | 2022 | 623 | 0.180 |
Why?
|
| Bacteria | 1 | 2024 | 468 | 0.180 |
Why?
|
| WT1 Proteins | 2 | 2014 | 20 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2018 | 782 | 0.180 |
Why?
|
| Transcription, Genetic | 4 | 2022 | 1156 | 0.180 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 441 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 156 | 0.180 |
Why?
|
| DNA Primers | 2 | 2016 | 543 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 329 | 0.170 |
Why?
|
| Azacitidine | 2 | 2023 | 139 | 0.170 |
Why?
|
| Gene Expression | 3 | 2022 | 1312 | 0.170 |
Why?
|
| Breast | 1 | 2021 | 292 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 394 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 399 | 0.170 |
Why?
|
| DNA Repair | 1 | 2021 | 359 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 15 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 6 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 891 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2019 | 321 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1077 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2018 | 43 | 0.160 |
Why?
|
| Neuralgia | 1 | 2018 | 30 | 0.160 |
Why?
|
| Ganglia, Spinal | 1 | 2018 | 75 | 0.160 |
Why?
|
| Oncogenes | 1 | 2018 | 92 | 0.160 |
Why?
|
| Caloric Restriction | 1 | 2017 | 14 | 0.150 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 37 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2015 | 21 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 492 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 612 | 0.150 |
Why?
|
| Microbiota | 1 | 2022 | 396 | 0.150 |
Why?
|
| Sex Chromosomes | 1 | 2017 | 57 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 659 | 0.140 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 28 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2017 | 161 | 0.140 |
Why?
|
| Heart | 1 | 2019 | 572 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 269 | 0.130 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2015 | 280 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 150 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2018 | 160 | 0.130 |
Why?
|
| Leukemia, Myeloid | 3 | 2010 | 249 | 0.130 |
Why?
|
| Binding Sites | 4 | 2023 | 1113 | 0.130 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2022 | 91 | 0.130 |
Why?
|
| Phenotype | 4 | 2024 | 2435 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2023 | 447 | 0.130 |
Why?
|
| Up-Regulation | 5 | 2018 | 729 | 0.130 |
Why?
|
| Macaca mulatta | 1 | 2017 | 465 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 51 | 0.120 |
Why?
|
| RNA Interference | 2 | 2018 | 378 | 0.120 |
Why?
|
| DNA | 4 | 2023 | 1308 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2012 | 531 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 559 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2022 | 3368 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 589 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2015 | 276 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 646 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 158 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 956 | 0.110 |
Why?
|
| Blood Donors | 1 | 2012 | 24 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 54 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 318 | 0.100 |
Why?
|
| Male | 14 | 2024 | 42012 | 0.100 |
Why?
|
| Colon | 1 | 2015 | 505 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 93 | 0.100 |
Why?
|
| Female | 14 | 2024 | 45759 | 0.100 |
Why?
|
| Histones | 1 | 2013 | 327 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 185 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 299 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2024 | 195 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2011 | 100 | 0.090 |
Why?
|
| Blood Platelet Disorders | 1 | 2010 | 9 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2018 | 3202 | 0.090 |
Why?
|
| Child, Preschool | 6 | 2017 | 3678 | 0.090 |
Why?
|
| Neuroblastoma | 1 | 2014 | 394 | 0.090 |
Why?
|
| Phthalazines | 2 | 2022 | 43 | 0.090 |
Why?
|
| Infant, Newborn | 4 | 2017 | 2445 | 0.090 |
Why?
|
| Cell Cycle | 3 | 2010 | 508 | 0.080 |
Why?
|
| Cell Line | 3 | 2019 | 2498 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 351 | 0.080 |
Why?
|
| Hematopoiesis | 3 | 2015 | 164 | 0.080 |
Why?
|
| Piperazines | 2 | 2022 | 280 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2879 | 0.080 |
Why?
|
| Cell Survival | 1 | 2010 | 980 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 2 | 2022 | 235 | 0.080 |
Why?
|
| Infant | 4 | 2017 | 3117 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2022 | 737 | 0.080 |
Why?
|
| Child | 7 | 2017 | 7089 | 0.080 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2023 | 8 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 2007 | 72 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2980 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2007 | 25 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 927 | 0.070 |
Why?
|
| Lymphopoiesis | 1 | 2007 | 48 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2006 | 20 | 0.070 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 88 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 37 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1520 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2006 | 91 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 884 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1571 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2022 | 1977 | 0.070 |
Why?
|
| Alleles | 2 | 2024 | 1132 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 269 | 0.060 |
Why?
|
| Protein Binding | 2 | 2022 | 1484 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2011 | 2009 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 166 | 0.060 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2004 | 2 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 135 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1945 | 0.060 |
Why?
|
| Asparaginase | 1 | 2004 | 35 | 0.060 |
Why?
|
| Bacteroides fragilis | 1 | 2024 | 43 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1427 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2005 | 1213 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2007 | 419 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 726 | 0.060 |
Why?
|
| Naloxone | 1 | 2023 | 64 | 0.060 |
Why?
|
| Fentanyl | 1 | 2023 | 67 | 0.060 |
Why?
|
| Ribonucleotides | 1 | 2023 | 13 | 0.060 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2023 | 13 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2024 | 262 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2023 | 30 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2005 | 466 | 0.060 |
Why?
|
| Entropy | 1 | 2023 | 39 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2003 | 54 | 0.050 |
Why?
|
| Acute Disease | 3 | 2012 | 838 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 65 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 92 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2022 | 83 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1647 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2018 | 131 | 0.050 |
Why?
|
| Nuclear Lamina | 1 | 2022 | 7 | 0.050 |
Why?
|
| Lamin Type A | 1 | 2022 | 26 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 3009 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 266 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6723 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 18932 | 0.050 |
Why?
|
| Haplotypes | 1 | 2024 | 637 | 0.050 |
Why?
|
| Genome, Human | 2 | 2018 | 767 | 0.050 |
Why?
|
| Esophagus | 1 | 2022 | 107 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2023 | 192 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2017 | 1988 | 0.050 |
Why?
|
| Plasmids | 1 | 2022 | 292 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 270 | 0.050 |
Why?
|
| Epithelium | 1 | 2022 | 325 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2017 | 797 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 74 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 440 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 141 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 247 | 0.050 |
Why?
|
| Genotype | 2 | 2021 | 1867 | 0.050 |
Why?
|
| Stem Cells | 1 | 2023 | 371 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1352 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 9157 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 25699 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 470 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 386 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 160 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1851 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 436 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1518 | 0.040 |
Why?
|
| Clone Cells | 2 | 2010 | 214 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 65 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 450 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2018 | 84 | 0.040 |
Why?
|
| Prognosis | 3 | 2018 | 3750 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 2018 | 98 | 0.040 |
Why?
|
| Genomic Library | 1 | 2018 | 33 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 126 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2005 | 4271 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 686 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 60 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 747 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 411 | 0.040 |
Why?
|
| K562 Cells | 1 | 2017 | 44 | 0.040 |
Why?
|
| Epigenomics | 1 | 2018 | 103 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 205 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 290 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 760 | 0.040 |
Why?
|
| Longevity | 1 | 2017 | 55 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2012 | 2837 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 1295 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 114 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 185 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 307 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2016 | 32 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2017 | 273 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 312 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 136 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 507 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 305 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 340 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 253 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3655 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 637 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1237 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 96 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1214 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 258 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 496 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1129 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2005 | 217 | 0.030 |
Why?
|
| Immunoglobulins | 2 | 2005 | 148 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 603 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2346 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1764 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 65 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 272 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 1057 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 170 | 0.030 |
Why?
|
| Adult | 3 | 2018 | 26348 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 13 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2005 | 389 | 0.030 |
Why?
|
| Telomerase | 1 | 2012 | 61 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2005 | 691 | 0.030 |
Why?
|
| Recurrence | 2 | 2005 | 1168 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 4041 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 82 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 63 | 0.020 |
Why?
|
| United States | 1 | 2023 | 6882 | 0.020 |
Why?
|
| Family | 1 | 2012 | 322 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 178 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 42 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 162 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 342 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2003 | 8178 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 354 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 452 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 968 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 341 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 2019 | 0.020 |
Why?
|
| Granzymes | 1 | 2007 | 94 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2331 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 27 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2006 | 72 | 0.020 |
Why?
|
| Czech Republic | 1 | 2005 | 3 | 0.020 |
Why?
|
| CD13 Antigens | 1 | 2005 | 5 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2005 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2005 | 32 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2006 | 126 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2005 | 51 | 0.020 |
Why?
|
| Neonatal Screening | 1 | 2006 | 62 | 0.020 |
Why?
|
| Neprilysin | 1 | 2005 | 41 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 261 | 0.020 |
Why?
|
| Glycosylation | 1 | 2005 | 129 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2005 | 285 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2536 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 172 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 2322 | 0.010 |
Why?
|
| Air Movements | 1 | 2002 | 2 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 24 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 539 | 0.010 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 90 | 0.010 |
Why?
|
| Quality Control | 1 | 2002 | 116 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2004 | 445 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 669 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 400 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 1718 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 409 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 1709 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 5319 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2746 | 0.010 |
Why?
|